Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

  • Leveraging small molecule inhibitors to improve CD19 CAR T cell immunotherapy for KMT2A-rearranged ALL. Lisa Niswander (Principal Investigator). NIH/NCI. 7/1/2024-7/1/2029.
  • MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication. Kara Kelly (Co-Principal Investigator). NIH/NCI. $4,215,730. 4/1/2024-3/1/2029.
  • AttaCH: Long term Safety, Tolerability, and Efficacy of Weekly SC Doses with TransCon CNP in Children and Adolescents with Achondroplasia. Teresa Quattrin (Principal Investigator). Ascendis. $39,372. 1/1/2023-1/1/2029.
  • Aligning With Schools To Help Manage Asthma (Project ASTHMA). Heather Lehman (Co-Investigator). NIH. 10/1/2023-9/1/2028.
  • Multimodal Learning for Contextually-Aware Longitudinal PET/CT Image Analysis. Kara Kelly (Co-Investigator). NIH/NIBIB. $2,333,292. 9/1/2023-8/1/2027.
  • Adaptation of an evidence-based family program for obesity Prevention in health care contexts: Testing outcomes and mechanisms with first-time military parents and their infants. Stephanie Anzman-Frasca (Co-Investigator). NIH. 7/1/2022-6/1/2027.
  • 52-Week Randomized Double Blind Placebo Controlled Multicenter Phase 2b st-Week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-Antagonist Monoclonal Antibody, for Preservation of Pancreatic ß-Cell Function in Adults and Adolescents with Newly Diagnosed Type 1 Diabetes on Insulin Therapy. Teresa Quattrin (Principal Investigator). Sanofi. 6/1/2024-6/1/2027.
  • Observational, Long-term Safety Study of Teplizumab in Patients with Stage 2 Type 1 Diabetes (T1D). Teresa Quattrin (Principal Investigator). Provention Bio and Sanofi. 6/1/2024-6/1/2027.
  • Efficacy and Safety of Subcutaneous Dupilumab in Participants with Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS). Heather Lehman (Co-Investigator). Sanofi. 5/1/2024-4/1/2027.
  • Relationship of prior coxsackievirus infection on the development of MIS-C. Mark Hicar (Principal Investigator). Wildermuth Foundation(regional). $31,600. 5/1/2024-12/1/2026.
  • The Alfiero Foundation Grant. Steven Lipshultz (Principal Investigator). The Alfiero Child Health Research Institute. 1/1/2021-12/1/2026.
  • Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence. Kara Kelly (Co-Investigator). National Cancer Institute. $3,234,730. 12/1/2021-11/1/2026.
  • A bilingual telemedicine-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors. Kara Kelly (Co-Investigator). Department of Defense. $1,280,246. 9/1/2022-8/1/2026.
  • Effects of pulse consumption on maternal and child health. Xiaozhong Wen (Principal Investigator). United States Department of Agriculture. $500,260. 8/1/2021-7/1/2026.
  • Assessment of Clonal Hematopoiesis and its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors. Kara Kelly (Co-Investigator). Department of Defense. $1,620,661. 7/1/2022-7/1/2026.
  • Sofia's Hope Coordinator/Second International Pediatric Cardio-Oncology Conference. Steven Lipshultz (Principal Investigator). Sofia's Hope. 6/1/2019-6/1/2026.
  • An Integrative Radiogenomic Framework for Predicting Treatment Failure in Children, Adolescents, and Young Adults with Hodgkin Lymphoma. Kara Kelly (Co-Investigator). Department of Defense. $388,750. 7/1/2022-6/1/2026.
  • PROACTIVE NYS (Prospective Observational Study of Asymptomatic cCMV Transmission to Infants for Virological Evaluation in New York State). Mark Hicar (Co-Investigator). NICHD. $145,000. 5/1/2024-5/1/2026.
  • Optimizing Chest Compressions for Bradycardia during Neonatal Resuscitation. Praveen Chandrasekharan (Principal Investigator). R01 - Eunice Kennedy Shriver National Institute of Child Health & Human Development. $1,500,000. 5/1/2021-4/1/2026.
  • Optimizing Chest Compressions for Bradycardia during Neonatal Resuscitation. Steven Lipshultz (Co-Investigator). NICHD. 5/1/2021-4/1/2026.